16.68
price up icon1.58%   0.26
 
loading
前日終値:
$16.42
開ける:
$16.5
24時間の取引高:
1.41M
Relative Volume:
1.20
時価総額:
$771.69M
収益:
$82.71M
当期純損益:
$-102.24M
株価収益率:
-4.545
EPS:
-3.67
ネットキャッシュフロー:
$-76.57M
1週間 パフォーマンス:
-4.14%
1か月 パフォーマンス:
-12.72%
6か月 パフォーマンス:
+77.64%
1年 パフォーマンス:
+40.05%
1日の値動き範囲:
Value
$15.86
$16.89
1週間の範囲:
Value
$15.86
$17.61
52週間の値動き範囲:
Value
$3.42
$21.71

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
名前
Urogen Pharma Ltd
Name
セクター
Healthcare (1140)
Name
電話
972 9 770 7601
Name
住所
9 HA'TA'ASIYA ST, RA'ANANA
Name
職員
253
Name
Twitter
@UroGenPharma
Name
次回の収益日
2025-03-10
Name
最新のSEC提出書
Name
URGN's Discussions on Twitter

URGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
URGN
Urogen Pharma Ltd
16.68 759.66M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-19 開始されました Piper Sandler Overweight
2025-06-16 アップグレード H.C. Wainwright Neutral → Buy
2025-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2025-04-16 開始されました Scotiabank Sector Outperform
2025-02-19 再開されました Ladenburg Thalmann Buy
2024-08-22 開始されました Guggenheim Buy
2023-02-08 ダウングレード Jefferies Buy → Hold
2022-04-27 開始されました Berenberg Buy
2020-04-16 繰り返されました H.C. Wainwright Buy
2020-04-13 繰り返されました H.C. Wainwright Buy
2020-01-09 開始されました National Securities Neutral
2019-05-30 開始されました JP Morgan Neutral
2019-05-29 開始されました Goldman Neutral
2019-01-29 開始されました H.C. Wainwright Buy
2018-11-08 再開されました Jefferies Buy
2018-04-04 アップグレード Raymond James Mkt Perform → Outperform
2018-01-02 開始されました Ladenburg Thalmann Buy
2017-11-15 繰り返されました Oppenheimer Outperform
2017-11-15 ダウングレード Raymond James Outperform → Mkt Perform
すべてを表示

Urogen Pharma Ltd (URGN) 最新ニュース

pulisher
Oct 12, 2025

Using AI based signals to follow UroGen Pharma Ltd.Long Setup & Fast Exit/Entry Strategy Plans - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛

Oct 11, 2025
pulisher
Oct 11, 2025

Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

What technical models suggest about UroGen Pharma Ltd.’s comebackJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com

Oct 11, 2025
pulisher
Oct 10, 2025

Chris Degnan Sells 2,203 Shares of Urogen Pharma (NASDAQ:URGN) Stock - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Understanding UroGen Pharma Ltd.’s price movementEarnings Beat & Safe Swing Trade Setups - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is UroGen Pharma Ltd. reversing from oversold territoryJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is UroGen Pharma Ltd. (UR8) stock a momentum leaderJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

UroGen Pharma CFO Degnan sells $37k in shares By Investing.com - Investing.com UK

Oct 09, 2025
pulisher
Oct 09, 2025

UroGen Pharma CFO Degnan sells $37k in shares - Investing.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is UroGen Pharma Ltd. (UR8) stock worth holding before Fed meeting2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

UroGen continues to climb after bladder cancer drug approval - MSN

Oct 07, 2025
pulisher
Oct 07, 2025

UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - Sahm

Oct 07, 2025
pulisher
Oct 06, 2025

Why UroGen Pharma Ltd. (UR8) stock trades below fair value2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Is UroGen Pharma Ltd a good long term investmentVolatility Index Analysis & Consistent Triple Returns - earlytimes.in

Oct 05, 2025
pulisher
Oct 05, 2025

UroGen Pharma Ltd. stock outlook for YEARPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How to recover losses in UroGen Pharma Ltd. stock2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Can swing trading help recover from UroGen Pharma Ltd. lossesJobs Report & High Accuracy Swing Entry Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com

Oct 03, 2025
pulisher
Oct 03, 2025

UroGen Pharma (URGN): Maintained Buy Rating by D. Boral Capital | URGN Stock News - GuruFocus

Oct 03, 2025
pulisher
Oct 03, 2025

Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Why UroGen Pharma Ltd. (UR8) stock stays on buy listsMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

UroGen’s bladder cancer treatment shows durable response in clinical trials By Investing.com - Investing.com Nigeria

Oct 03, 2025
pulisher
Oct 03, 2025

Can machine learning forecast UroGen Pharma Ltd. recoveryAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ - GlobeNewswire

Oct 02, 2025
pulisher
Oct 02, 2025

Can IL FS Transportation Networks Limited Deliver Margin Expansion Amid InflationEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

What drives UroGen Pharma Ltd stock priceStock Market Trends & Smart Beta Strategies That Actually Work - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

URGN: UroGen Pharma's ZUSDURI Shows Promising Results for Bladder Cancer - GuruFocus

Oct 02, 2025
pulisher
Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times

Oct 02, 2025
pulisher
Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewswire

Oct 02, 2025
pulisher
Oct 02, 2025

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 02, 2025
pulisher
Oct 01, 2025

Urogen Pharma (NASDAQ:URGN) Trading Down 5.9%Here's Why - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

UroGen Pharma Hits Day High with 15.59% Surge, Outperforming S&P 500 - Markets Mojo

Oct 01, 2025

Urogen Pharma Ltd (URGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Urogen Pharma Ltd (URGN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schoenberg Mark
Chief Medical Officer
Sep 08 '25
Sale
19.11
871
16,645
149,025
Smith Jason Drew
General Counsel
Sep 08 '25
Sale
19.11
1,520
29,047
43,305
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
大文字化:     |  ボリューム (24 時間):